Less is More? First Impressions From COSMIC-313
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Investigation"
DOI: 10.1080/07357907.2022.2136681
Abstract: Abstract The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell… read more here.
Keywords: oncology; cell; less first; first impressions ... See more keywords
A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.tps5102
Abstract: TPS5102Background: Cabozantinib (C) inhibits tyrosine kinases involved in tumor growth, angiogenesis, and immune regulation, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER), and may promote... read more here.
Keywords: phase iii; study cosmic; cosmic 313; 313 cabozantinib ... See more keywords